By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

“Stories of Hope” shares the stories of the people and scientists at the forefront of advancing medical science and pushing ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Robert F. Kennedy’s position on vaccines is profoundly "anti-science" and making progress would require a new health secretary, Pfizer Chief Executive Albert Bourla said Wednesday. “I have very ...

All three of these stocks sport dividend yields above 6%.